View
3
Download
0
Category
Preview:
Citation preview
Vaccine Industry Consultation
Humanitarian Mechanism for Access to Affordable Vaccines
Tania Cernuschi, IVB, WHO
www.who.int
September 2019
Establishment of Humanitarian Mechanism
2
Launched by WHO, UNICEF, MSF, Save the Children on 1 May 2017Following June 2016 meeting co-organised by MSF and WHO to address key barrier of obtaining affordable vaccines in humanitarian emergencies in timely manner
Main aim: Facilitate timely access to affordable supply for entities such CSOs, Governments or UN Agencies who procure on behalf of populations facing humanitarian emergencies
Current offers are for PCV vaccine from GSK and Pfizer at approximately US$ 3 per dose
3
Principles
• Ensure timely and affordable access to vaccine supply for humanitarian emergencies
• Align with WHO’s guidance: ‘Vaccination in acute humanitarian emergencies: A
framework for decision making’
• Enhance granting of lowest price to procuring entity while avoiding interference with commercial strategy of companies
• Enable any entity with procurement capacity to purchase vaccines directly from the manufacturer for speed and efficiency
• Promote information and transparency of manufacturers’ price offers for humanitarian emergencies and predictability of process
4
Key Features of the Humanitarian Mechanism
• Promotion of manufacturer supply commitments; price offers made publicly are recorded and published, including their terms and conditions as indicated by suppliers
• Management & coordination of requests: no duplication; rapid notification to all parties
• Request for access to supply is submitted to Verification Body at WHO: coordinated through WHE; collaboration between WHE and IVB
• Procurement: directly with manufacturer or through UNICEF SD• Annual monitoring of supply offers’ use; review modus operandi as required
5
Overview of Requests
• 32 request for a total of 856,000 doses
• Eight countries/emergency situations supplied
• 68% of doses going to non-GAVI, non-PAHO middle income (Algeria, Greece, Lebanon, Syria)
• Total population targeted: 740,000
Greece 2 requestsTotal target pop: 14,400
Syria - 8 requestsTotal target pop: 256,522
Algeria -1 request Total target pop: 5,680
CAR - 6 requestsTotal target pop: 153,141
Lebanon – 4 requestsTotal target pop: 103,872
Niger 3 requestsTotal target pop: 19,500 NIgeria 2 requests
Total target pop: 82,800
South Sudan - 4requestsTotal target pop: 48,140
6
Performance February 2017 to July 2019
1 11
3
6
114
11
2 1
CRA (via UNICEF)
IOM (via UNICEF)
MSF
MSF-Belgium
MSF-France
MSF-Greece
MSF-Spain
MSF-Switzerland
MSF-UNRWA
UNICEF
UNRWA (via UNICEF)
Figure. Requesting entities (n=32) Analysis of 32 requests• 14 in 2017, 8 in 2018, 10 in 2019 (so far)• Large majority of requests are submitted
by MSF (over 80%)
Equal split between PCV10 and PCV13• 16 requests for PCV 10 (GSK)• 16 requests for PCV13 (Pfizer)
Timeliness• Median time to from request to approval: 2
days• 1 delay over Christmas (25 days)
7
Analysis of 2017 and 2018 Reports
Implementation (14 reports available from MSF)
• 5 countries• Non-vaccination mainly due to security or
logistic issues (cold chain failure)• Some un-used doses still in MSF stock
available for use
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
CentralAfrican
Republic
Niger Nigeria NorthernSyria
South Sudan Syria
Doses used Doses procured
Figure. Doses procured and used per country (14 reports)
2017 2018 TOTALDoses Requested 296,002 38,400 334,402
Doses used 176,115 20,956 197 071
8
Does the mechanism meet its aim? • Demonstrated success in rapid and predictable access to PCV in
humanitarian emergencies and direct procurement for CSOs• Granted transparent and low price to countries and populations beyond
Gavi, while avoiding interference with commercial strategy of companies• Management & coordination of requests: rapid notification / approval • Collected important information on demand for vaccines in emergency and
related challengesBUT
• Need to further promote use beyond MSF & UNICEF• Need to further promote supply offers beyond PCV• How can we provide access also to Governments?
Lessons Learnt to Date
9
Supply - expand the vaccines available• The current priority vaccines are Typhoid and Rotavirus vaccines• Focus is on prequalified vaccines• Information letter going out to specific manufacturers of prequalified
vaccines and to DCVMN and IFPMA
Demand: • Strengthen demand quantification for PCV, Rotavirus and Typhoid
vaccines through implementation partners• Increase range of CSOs requesting vaccines from the mechanism –
information letter going out to humanitarian/emergency organisations
Way Forward
Thank you
WHO
20, Avenue Appia1211 Geneva
Switzerland
Recommended